Updated:
Senzime AB
Senzime AB is a Swedish medtech firm developing perioperative monitoring sensors for anesthesia and critical care.
Senzime AB
Senzime AB was originally founded in Sweden with its headquarters in Uppsala; the company's core innovation is the TetraSens platform, a sensor system for tracking neuromuscular blockade and other vital parameters during surgery (public record). The firm targets the global operating-room monitoring market, a segment estimated at several billion dollars. Senzime has received CE marking for its products and markets them in Europe, with U.S. FDA clearance still in progress as of 2024. Strategically, Senzime operates as a commercial-stage medtech company rather than a pure research entity. Its product pipeline includes sensors for depth of anesthesia and muscle relaxation, devices meant to reduce postoperative complications. The company's financials are publicly reported; it has raised capital through equity offerings on the Nasdaq Stockholm exchange. Senzime's larger competitors include Medtronic and GE Healthcare, but its niche focus on neuromuscular monitoring differentiates it. Team size and specific professionals are not publicly confirmed; the firm's operational presence is centered in Uppsala with sales and distribution across Europe. As of late 2024, Senzime had not announced major partnerships or institutional ownership that would suggest a family-office backing. The company's capital structure suggests it is publicly held, with no identified single-family-office or multi-family-office involvement. Senzime's structural differentiator lies in its sensor-based monitoring platform, which is designed for one-patient use to reduce cross-contamination — a feature increasingly valued in post-COVID healthcare. The company's regulatory posture also sets it apart: while many medtech firms exit to larger players, Senzime remains independent, pursuing a direct commercialization strategy.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
Europe
Country
Sweden
City
Uppsala
Corporate office
Uppsala, Sweden
Frequently asked questions
What is Senzime AB's primary product line?
Senzime AB develops the TetraSens platform, a portfolio of sensors for monitoring neuromuscular blockade, depth of anesthesia, and vital signs during surgery. The devices are designed for single-patient use to reduce cross-infection risks (public record).
Where does Senzime AB sell its products?
Senzime markets its products in Europe under CE marking, with a focus on operating rooms and intensive care units. As of 2024, the company was pursuing FDA clearance for the U.S. market (per public filings).
Who are Senzime AB's main competitors?
Senzime competes with larger medtech firms such as Medtronic, GE Healthcare, and Nihon Kohden in the perioperative monitoring space. However, its specific focus on neuromuscular monitoring differentiates it from broader patient monitoring systems.
Is Senzime AB a family office or asset manager?
No, Senzime AB is a publicly traded medical-technology company listed on Nasdaq Stockholm. Its ownership structure does not indicate family-office backing; it is a commercial medtech firm.
What regulatory approvals does Senzime hold?
Senzime products have CE marking for sale in the European Economic Area. FDA clearance for the U.S. market has been reported as a development goal, though no timeline is publicly confirmed (public record).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: